ABIOMED INC. news, videos and press releases
For more news please use our advanced search feature.
ABIOMED INC. - More news...
ABIOMED INC. - More news...
- FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
- First Patients in the World Treated with Impella RP Flex with SmartAssist
- ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
- INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of ABIOMED, Inc. - ABMD
- ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
- SHAREHOLDER ALERT: Weiss Law Investigates Abiomed, Inc.
- Thinking about buying stock in Atlas Corp, Unity Biotechnology, Abiomed, Tilray, or Pfizer?
- ABMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ABIOMED, Inc. Is Fair to Shareholders
- Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
- Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
- Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
- MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
- Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
- U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
- Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
- Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
- Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
- Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
- Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
- FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
- TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
- Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
- ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
- Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
- Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
- Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
- SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
- Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
- World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
- Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification